If I was a betting man, and I am, I would guess that the data they are receiving is so strong that they will need a US listing in order to get good or great value for the shareholders. The Biogen news a couple of weeks ago sent their market cap up about US$13 billion on news that just slowed progress by 31%. Yes I know that value increase didn't stick but North of the boarder here we generally don't get that kind of lift on any news.

I'm really wondering if this First In Class drug is about to rock the world with unheard of results  when the final data comes out. The great data could be in all areas but  specifically on the cognitive function arm of the trial. Virtually nothing was said for close to 2.5 years and now in the last 5 months or so it seems like it is mentioned once or twice per month. It may now be time to begin exploiting the data that they have been receiving and get full value when they are able to tell the world what they believed they have had for many years now.

It sure would be nice to have a DSMB report out in the next couple of weeks with an FA.

dyodd

tada